Glecaprevir

Hepatitis C Virus NS3/4A Protease Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Glecaprevir is an onp drug in the Hepatitis C Virus NS3/4A Protease Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2017. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 1A2 Inhibitors and Cytochrome P450 3A Inhibitors. DrugCentral lists 1 molecular target, including NS5B. Recorded indications include Chronic hepatitis C and Compensated cirrhosis.

• Approval status: onp (first approved 2017 by the EMA).
• Drug class: Hepatitis C Virus NS3/4A Protease Inhibitor.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 1A2 Inhibitors; Cytochrome P450 3A Inhibitors.
• Molecular targets: NS5B (1 listed in DrugCentral).
• Indications: Chronic hepatitis C and Compensated cirrhosis.
• ATC code: J05AP57 (Antivirals for treatment of HCV infections).
• Molecular formula: C38H46F4N6O9S; molecular weight 838.87 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Chronic hepatitis C
• Compensated cirrhosis

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 1A2 Inhibitors; Cytochrome P450 3A Inhibitors; HCV NS3/4A Protease Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-Glycoprotein Inhibitors; UGT1A1 Inhibitors
• Established pharmacologic class: Hepatitis C Virus NS3/4A Protease Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
NS5B protein	NS5B	unknown	Ki 10.28

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2017-09-27	PMDA	—	AbbVie GK
2017-08-03	FDA	—	ABBVIE INC
2017-07-26	EMA	—	AbbVie Deutschland GmbH & Co. KG

ATC classification

ATC code	Therapeutic hierarchy
J05AP57	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections

Chemical structure

• Molecular formula: C₃₈H₄₆F₄N₆O₉S
• Molecular weight: 838.87 g/mol
• CAS number: 1365970-03-1
• InChIKey: MLSQGNCUYAMAHD-ITNVBOSISA-N
• PubChem CID: 66828839

CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC\C=C\C(F)(F)C2=NC3=CC=CC=C3N=C2O[C@@H]2C[C@H](N(C2)C1=O)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Glecaprevir used for?

DrugCentral lists the following indications for Glecaprevir: Chronic hepatitis C and Compensated cirrhosis.

How does Glecaprevir work?

Glecaprevir is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 1A2 Inhibitors and Cytochrome P450 3A Inhibitors; its molecular targets in DrugCentral include NS5B.

When was Glecaprevir first approved?

Glecaprevir was first approved by the EMA in 2017.

What drug class does Glecaprevir belong to?

Glecaprevir is in the Hepatitis C Virus NS3/4A Protease Inhibitor class.

What is the chemical formula of Glecaprevir?

Glecaprevir has the molecular formula C38H46F4N6O9S and a molecular weight of 838.87 g/mol.

Sources

• DrugCentral drug card 5243 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3545363 — compound record and bioactivity
• PubChem CID 66828839 — chemical identifiers
• DrugBank DB13879 — drug record
• FDA UNII K6BUU8J72P — substance identity
• DailyMed: FDA labels for Glecaprevir — current prescribing information (label search)

How this page is built: methodology · editorial policy & corrections.